Protection against progressive leishmaniasis by IFN-β1

Journal of Immunology

Volumn 172, Issue 12, 2004, Pages 7574-7582

  Mattner, Jochen ^a,d   Wandersee Steinhäuser, Alexandra ^a   Pahl, Andreas ^a   Röllinghoff, Martin ^a   Majeau, Gerard R ^b   Hochman, Paula S ^b   Bogdan, Christian ^a,c,e  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b BIOGEN   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; MESSENGER RNA; STAT1 PROTEIN; STAT4 PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOLOGY; IMMUNOREGULATION; LEISHMANIASIS; LYMPH NODE CELL; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 2942565907     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.12.7574     Document Type: Article

References (65)

1. Bogdan, C., A. Gessner, and M. Röllinghoff. 1993. Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology 189:356.
2. Bogdan, C., M. Röllinghoff, and A. Diefenbach. 1999. Nitric oxide in leishmaniasis: from antimicrobial activity to immunoregulation. In Nitric Oxide and Infection. F. Fang, ed. Kluwer Academic/Plenum, New York, p. 361.
3. Sacks, D. L., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845.
4. Solbach, W., and T. Laskay. 2000. The host response to Leishmania infection. Adv. Immunol. 74:275.
5. Bogdan, C., N. Donhauser, R. Döring, M. Röllinghoff, A. Diefenbach, and M. G. Rittig. 2000. Fibroblasts as host cells in latent leishmaniosis. J. Exp. Med. 191:2121.
6. Launois, P., H. Himmelreich, F. Tacchini-Cottier, G. Milon, and J. A. Louis. 1999. New insight into the mechanisms underlying Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Microbes Infect. 1:59.
7. Fowell, D. J., and R. M. Locksley. 1999. Leishmania major infection of inbred mice: unmasking genetic determinants of infectious diseases. BioEssays 21:510.
8. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, interferon-γ -independent mechanism. J. Exp. Med. 171:115.
9. Sypek, J. P., C. L. Chung, S. H. E. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type I immune response. J. Exp. Med. 177:1797.
10. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505.
11. Scott, P. 1991. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:3149.
12. Roberts, R. M., L. Liu, Q. Guo, D. Leaman, and J. Bixby. 1998. The evolution of the type I interferons. J. Interferon Cytokine Res. 18:805.
13. + blood dendritic cells are potent producers of IFN-α in response to in vitro HIV-1 infection. J. Immunol. 152:4649.
14. Gresser, I. 1997. Wherefore interferon? J. Leukocyte Biol. 61:567.
15. Bogdan, C. 2000. The function of type 1 interferons in antimicrobial immunity. Curr. Opin. Immunol. 12:419.
16. Biron, C. A. 2001. Interferons α and β as immune regulators: a new look. Immunity 14:661.
17. Colonna, M., A. Krug, and M. Cella. 2002. Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol. 14:373.
18. Santini, S. M., C. Lapenta, M. Logozzi, S. Parlato, M. Spada, T. Di Pucchio, and F. Belardelli. 2000. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191:1777.
19. Dalod, M., T. A. Hamilton, R. Salomon, T. P. Salazar-Mather, S. C. Henry, J. D. Hamilton, and C. A. Biron. 2003. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon-α/β. J. Exp. Med. 197:885.
20. Krug, A., R. Veeraswamy, A. Pekosz, O. Kanagawa, E. R. Unanue, M. Colonna, and M. Cella. 2003. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J. Exp. Med. 197:899.
21. Brassard, D. L., M. J. Grace, and R. W. Bordens. 2002. Interferon-α as an immunotherapeutic protein. J. Leukocyte Biol. 71:565.
22. Filippini, G., L. Munari, B. Incorvaia, G. C. Ebers, R. D'Amico, and G. P. A. Rice. 2003. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545.
23. Diefenbach, A., H. Schindler, N. Donhauser, E. Lorenz, T. Laskay, J. MacMicking, M. Röllinghoff, I. Gresser, and C. Bogdan. 1998. Type 1 interferon (IFN-α/β) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 8:77.
24. Mattner, J., H. Schindler, A. Diefenbach, M. Röllinghoff, I. Gresser, and C. Bogdan. 2000. Regulation of type 2 NO synthase by type I interferons in macrophages infected with Leishmania major. Eur. J. Immunol. 30:2257.
25. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M. K. Gately, J. A. Louis, and G. Alber. 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1553.
26. Vodjdani, G., C. Coulombel, and J. Doly. 1988. Structure and characterization of a murine chromosomal fragment containing the interferon-β gene. J. Mol. Biol. 204:221.
27. Runkel, L., C. deDios, M. Karpusas, M. Betzenhauser, C. Muldowney, M. Zafari, C. D. Benjamin, S. Miller, P. S. Hochman, and A. Whitty. 2000. Systematic mutational mapping of sites on human interferon-β-1a that are important for receptor binding and functional activity. Biochemistry 39:2538.
28. Stenger, S., N. Donhauser, H. Thüfing, M. Röllinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501.
29. Blos, M., U. Schleicher, F. J. Rocha, U. Meissner, M. Röllinghoff, and C. Bogdan. 2003. Organ-specific and stage-dependent control of Leishmania major infection by inducible nitric oxide synthase and phagocyte NADPH oxidase. Eur. J. Immunol. 33:1224.
30. Bogdan, C., H. Thüring, M. Dlaska, M. Röllinghoff, and G. Weiss. 1997. Mechanism of suppression of macrophage nitric oxide release by IL-13. J. Immunol. 159:4506.
31. Diefenbach, A., H. Schindler, M. Röllinghoff, W. Yokoyama, and C. Bogdan. 1999. Requirement for type 2 NO-synthase for IL-12 responsiveness in innate immunity. Science 284:951.
32. Fehninger, T. A., M. H. Shah, M. J. Turner, J. B. van Deusen, S. P. Whitman, M. A. Cooper, K. Suzuki, M. Wechser, F. Goodsaid, and M. A. Caligiuri. 1999. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162:4511.
33. Foster, G. R., and N. B. Finter. 1998. Are all type I human interferons equivalent? J. Viral Hepat. 5:143.
34. Cull, V. E., E. J. Bartlett, and C. M. James. 2002. Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology 106:428.
35. Domanski, P., O. W. Nadeau, L. C. Platanias, E. Fish, M. Kellum, P. Pitha, and O. R. Colamonici. 1998. Differential use of the βL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFN-α2 and IFN-β. J. Biol. Chem. 273:3144.
36. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
37. Laskay, T., M. Röllinghoff, and W. Solbach. 1993. Natural killer cells participate in the early defense against Leishmania major infection in mice. Eur. J. Immunol. 23:2237.
38. Scott, P. A., and J. A. Farrell. 1981. Experimental cutaneous leishmaniasis. I. Nonspecific immunodepression in BALB/c mice infected with Leishmania tropica. J. Immunol. 127:2395.
39. Solbach, W., M. Lohoff, H. Streck, P. Rohwer, and M. Röllinghoff. 1987. Kinetics of cell-mediated immunity developing during the course of Leishmania major infection in "healer" and "non-healer" mice: progressive impairment of response to and generation of interleukin-2. Immunology 62:485.
40. + T cells resulting in a state of unresponsiveness to IL-12. J. Immunol. 161:6156.
41. Tough, D. F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type 1 interferon in vivo. Science 272:1947.
42. Freudenberg, M. A., T. Merlin, C. Kalis, Y. Chvatchko, H. Stübig, and C. Galanos. 2002. Cutting edge: a murine IL-12-independent pathway of IFN-γ induction by Gram-negative bacteria based on STAT4 activation by type 1 IFN and IL-18 signaling. J. Immunol. 169:1665.
43. Nguyen, K. B., W. T. Watford, R. Salomon, S. R. Hofmann, G. C. Pien, A. Morinobu, M. Gadina, J. J. O'Shea, and C. A. Biron. 2002. Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 297:2063.
44. Stenger, S., H. Thüring, M. Röllinghoff, and C. Bogdan. 1994. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. 180:783.
45. Meraz, M. A., J. M. White, K. C. F. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the Jak-STAT signaling pathway. Cell 84:431.
46. Gao, J. J., M. B. Filla, M. J. Fultz, S. N. Vogel, S. W. Russell, and W. J. Murphy. 1998. Autocrine/paracrine IFN-α/β mediates the lipopolysaccharide-induced activation of transcription factor Stat1α in mouse macrophages: pivotal role of Stat1α in induction of the inducible nitric oxide synthase gene. J. Immunol. 161:4803.
47. Kinjyo, I., T. Hanada, K. Inagaki-Ohara, H. Mori, D. Aki, M. Ohishi, H. Yoshida, M. Kubo, and A. Yoshimura. 2002. SOCS1/Jab is a negative regulator of LPS-induced macrophage activation. Immunity 17:583.
48. van den Broek, M. F., U. Müller, S. Huang, R. M. Zinkernagel, and M. Aguet. 1995. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148:5.
49. Brierley, M. M., and E. N. Fish. 2002. IFN-α/β receptor interactions to biologic outcomes: understanding the circuitry. J. Interferon Cytokine Res. 22:835.
50. Brooks, C. G., M. Holscher, and D. Urdal. 1985. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin-2, interferon, and specific antigen. J. Immunol. 135:1145.
51. van Hoegen, P. 1995. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol. Lett. 47:157.
52. Sato, K., S. Hida, H. Takayanagi, T. Yokochi, N. Kayagaki, K. Takeda, H. Yagita, K. Okumura, N. Tanaka, T. Taniguchi, and K. Ogasawara. 2001. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 31:3138.
53. Freshman, M. M., T. C. Merigan, J. S. Remington, and I. E. Brownlee. 1966. In vitro and in vivo antiviral action of an interferon-like substance induced by Toxoplasma gondii. Proc. Soc. Exp. Biol. Med. 123:862.
54. Rothfuchs, A. G., D. Gigliotti, K. Palmbad, U. Andersson, H. Wigzell, and M. E. Rottenberg. 2001. IFN-α/β-dependent IFN-γ secretion by bone marrow-derived macrophages controls an intracellular bacterial infection. J. Immunol. 167:6453.
55. Remoli, M. E., E. Giacomini, G. Lutfalla, E. Dondi, G. Orefici, A. Battistine, G. Uze, S. Pellegrini, and E. M. Coccia. 2002. Selective expression of type I interferon genes in human dendritic cells infected with Mycobacterium tuberculosis. J. Immunol. 169:366.
56. Manca, C., L. Tsenova, A. Bergtold, S. Freeman, M. Tovey, and J. M. Musser. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with the induction of IFN-α/β. Proc. Natl. Acad. Sci. USA 98:5752.
57. Denis, M. 1991. Recombinant murine β interferon enhances resistance of mice to systemic Mycobacterium avium infection. Infect. Immun. 59:1857.
58. Kierszenbaum, F., and G. Sonnenfeld. 1982. Characterization of the antiviral activity produced during Trypanosoma cruzi infection and protective effects of exogenous interferon against experimental Chagas' disease. J. Parasitol. 68:194.
59. Orellana, M. A., Y. Suzuki, F. Araujo, and J. S. Remington. 1991. Role of β interferon in resistance to Toxoplasma gondii infection. Infect. Immun. 59:3287.
60. Fujiki, T., and A. Tanaka. 1988. Antibacterial activity of recombinant mouse β interferon. Infect. Immun. 56:548.
61. Schleicher, U., J. Mattner, M. Blos, H. Schindler, M. Röllinghoff, M. Karaghiosoff, M. Müller, G. Werner-Felmayer, and C. Bogdan. 2004. Control of Leishmania major in the absence of Tyk2 kinase. Eur. J. Immunol. 34:519.
62. Cousens, L. P., J. S. Orange, H. C. Su, and C. A. Biron. 1997. Interferon-α/β inhibition of interleukin-12 and interferon-γ production in vitro and endogenously during viral infection. Proc. Natl. Acad. Sci. USA 94:634.
63. da Silva, A. J., M. Brickelmaier, G. R. Majeau, A. V. Lukashin, J. Peyman, A. Whitty, and P. S. Hochman. 2002. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α2b vs. IFN-β1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J. Interferon Cytokine Res. 22:173.
64. Bosio, E., C. L. Cluning, and M. W. Beilharz. 2001. Low-dose orally administered type 1 interferon reduces splenic B cell numbers of mice. J. Interferon Cytokine Res. 21:721.
65. Mogensen, K. E., M. Lewerenz, J. Reboul, G. Lutfalla, and G. Uze. 1999. The type 1 interferon receptor: structure, function and evolution of a family business. J. Interferon Cytokine Res. 19:1069.